Gilead Sciences Inc. (GILD)
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day.
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?
Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding trading day.
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.
Gilead Sciences: The Market Is Underestimating Its Growth Runway
Gilead Sciences offers a compelling long-term value opportunity after a significant pullback, with a "Buy" rating reaffirmed. GILD's core HIV franchise drives 72% of sales, with robust growth from Biktarvy and rapid adoption of Yeztugo, now expected to reach $1 billion in annual sales. Management raised 2026 revenue growth guidance to 5.5% at midpoint, citing strong HIV performance and momentum in oncology with Trodelvy.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.
